Billions in Share Buybacks to Stabilize Markets? As Stock Prices Remain Weak, Leading Pharmaceutical Firms Launch a 'Valuation Defense Campaign'

① Amid sustained downward pressure on share prices, several pharmaceutical companies—including Sino Biopharm, Akeso, and Wuxi Apptec—have successively announced share repurchase or management buy-in plans; ② Industry insiders believe that such repurchases can help restore market sentiment, but a meaningful re-rating of the sector will still depend on the consistent realization of commercialization and global expansion capabilities.

cls.cnJun 15 17:06

Sci-Tech Innovation Board Q1 earnings show accelerated improvement; what other key signals did the latest issue of the Shanghai Stock Exchange's 'Sci-Tech Innovation Board Regulatory Express' reveal?

① The Shanghai Stock Exchange recently issued the third issue of 2026 of the 'STAR Market Regulatory Express,' focusing on the latest developments and case notifications in the STAR Market segment, offering in-depth interpretations of regulatory guidance and clarifying key rule provisions to serve as a reference for market participants; ② This special issue summarizes regulatory Q&A content, including self-inspection requirements for refinancing proposals, and presents three types of typical cautionary cases: financial statement fraud and deceptive listing, significant revisions to earnings forecasts, and textual errors in periodic reports.

cls.cnJun 14 10:41

The queue of companies seeking to list on the A-share market continues to grow—which Hong Kong-listed stocks are currently advancing their A-share listing processes?

① Data show that at least 10 Hong Kong-listed companies are currently advancing their A-share listing processes; ② Investment banking professionals at Ping An Securities noted that this round of 'H-to-A' listings will be characterized by structural, steady expansion and significant sectoral differentiation, with a relatively low probability of a market-wide surge.

cls.cnJun 3 08:54

OS Head-to-Head Victory! Akeso's Star Bispecific Antibody Challenges the First-Line 'Gold Standard' in Lung Squamous Cell Carcinoma—But the Final Chapter Has Yet to Be Written

① The HARMONi-6 study has become the world’s first Phase III trial in lung cancer to demonstrate statistically significant and clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) with a PD-1 inhibitor combined with chemotherapy; ② However, the findings from HARMONi-6 are not yet the final word—the market continues to await further answers.

cls.cnJun 1 16:44

Is the online prescription drug sales boom coming to an end? The initial impact of the 'dual new regulations' on prescription drugs is becoming evident, with some weight-loss medications adjusting their online sales channels.

① Online sales channels for certain weight-loss medications have already undergone adjustments, with differentiated sales pathways emerging across products and indications; ② The 'Guidelines' and the 'Regulations' now operate in regulatory synergy, steering online prescription drug sales back from a focus on 'traffic and conversion' toward a medical logic centered on 'prescription review and compliance'; ③ Competitive priorities in the online retail sector for prescription drugs are shifting toward compliance capabilities, integration of medical resources, and patient service excellence.

cls.cnJun 1 11:40

Akeso Lung Cancer Drug Improved Survival, Challenging Standard Treatment

Seeking AlphaJun 1 00:21